Angelini Pharma, as a pharmaceutical company deeply committed to mental health, actively contributes to this cause also through multidisciplinary initiatives like Headway.
Headway – A new roadmap in Mental Health, a collaborative effort by Angelini Pharma and the Italian think tank The European House – Ambrosetti, seeks to stimulate strategic reflection, analysis, dialogue, and comparison of European experiences in the management and treatment of mental health disorders.
Monitoring the responsiveness of a country, assessing its trend over time and comparing it to other systems, allows for a dynamic and more complete picture of the effects of health, social, employment, educational and environmental policy interventions on the Mental Health status of the population.
As such, every year the Headway Mental Health Index provides a multidimensional picture of key aspects of Mental Health measuring a limited number of indicators, selected based on the comparability and availability of data from the EU-27 + UK Countries.
In 2023, the Index encompasses 54 key performance indicators and focuses on three macro-areas: the determinants of mental health, the mental health status of a population and the responsiveness of national health systems to people’s needs relating to healthcare, workplaces, schools, and society in general. <
A preview of the entire report is available in the op-ed by Jacopo Andreose, CEO of Angelini Pharma, on EURACTIV, where he anticipates some findings from the Headway Report relating to mental health in the workplace and schools. Namely, 20% of children experience mental health problems during school years, while mental health issues affect up to 20% of the working-age population, leading to reduced productivity and presenteeism.
The full updated edition of the Headway - Mental Health Index 3.0 will be presented at the European Parliament on October 25, 2023.